Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model.

Abstract

The antileishmanial efficacy of the reference drug N-methylglucamine antimoniate (Glucantime) was evaluated in groups of rhesus monkeys with acute and chronic Leishmania (Viannia) braziliensis cutaneous infection. The therapeutic responses in experimental animals to either a low dose (5 mg/kg body wt/day for 28 days) or a routine dose (20 mg/kg/day for 28 days) of pentavalent antimony were similar to those reported in the human disease. Primates were cured of their lesions after treatment, but with cryptic parasitism and/or relapse. The rhesus model of L. (V.) braziliensis cutaneous leishmaniasis therefore provides an additional resource for preclinical trials with newer drugs.

• Authors: A Teva, R Porrozzi, M P Oliveira-Neto, G Júnior Grimaldi
• Journal: The Journal of parasitology (J Parasitol) Vol. 91 Issue 4 Pg. 976-8 (Aug 2005) ISSN: 0022-3395 [Print] United States
• PMID: 17089782 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiprotozoal Agents
• Organometallic Compounds
• Meglumine
• Meglumine Antimoniate

Topics

• Animals
• Antiprotozoal Agents (administration & dosage, pharmacology, therapeutic use)
• Disease Models, Animal
• Female
• Immunity, Cellular
• Injections, Intramuscular
• Leishmania braziliensis (drug effects)
• Leishmaniasis, Cutaneous (drug therapy, immunology)
• Macaca mulatta
• Male
• Meglumine (administration & dosage, pharmacology, therapeutic use)
• Meglumine Antimoniate
• Organometallic Compounds (administration & dosage, pharmacology, therapeutic use)